| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | DAWNRAYS PHARMA (02348): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER - NOTICE OF PUBLICATION OF 2026 INTERIM REPORT | 3 | HKEx | ||
| 17.09. | DAWNRAYS PHARMA (02348): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF 2026 INTERIM REPORT | - | HKEx | ||
| DAWNRAYS PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 17.09. | DAWNRAYS PHARMA (02348): 2026 INTERIM REPORT | 1 | HKEx | ||
| 28.08. | DAWNRAYS PHARMA (02348): INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2026 AND CLOSURE OF REGISTER OF MEMBERS | 1 | HKEx | ||
| 28.08. | DAWNRAYS PHARMA (02348): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 | 1 | HKEx | ||
| 14.08. | DAWNRAYS PHARMA (02348): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | DAWNRAYS PHARMA (02348): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 18.06. | DAWNRAYS PHARMA (02348): DISCLOSEABLE TRANSACTION - INVESTMENT IN A LIMITED PARTNERSHIP | - | HKEx | ||
| 27.05. | DAWNRAYS PHARMA (02348): VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT | 3 | HKEx | ||
| 22.05. | DAWNRAYS PHARMA (02348): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026 | 1 | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER - NOTICE OF PUBLICATION OF 2025 ANNUAL REPORT, CIRCULAR, NOTICE ... | 1 | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF 2025 ANNUAL REPORT, CIRCULAR, NOTICE ... | 1 | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING OF THE COMPANY TO BE HELD ON FRIDAY, 22 MAY 2026 (OR AT ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | DAWNRAYS PHARMA (02348): 2025 ANNUAL REPORT | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| ETON PHARMACEUTICALS | 55,42 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,685 | -0,04 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 18,420 | 0,00 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| PFIZER | 24,735 | +0,18 % | AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot | ||
| LB PHARMACEUTICALS | 37,080 | +0,24 % | Needham initiates LB Pharmaceuticals stock with buy rating | ||
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories | ||
| BIOHAVEN | 12,870 | 0,00 % | Biohaven Ltd.: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 |
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on... ► Artikel lesen | |
| SCHOTT PHARMA | 24,550 | +0,82 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,555 | +0,11 % | Aquestive appoints Rich Daly to board of directors | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead |